WMA Declaration of Helsinki – Ethical Principles f... ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Ask the Heart Doctor | Heart Valve Disease and Sur...
Drug candidate slows motor neuron disease progress...
A Professional Overview of Hypertension ...
Long-term physical activity protects against metabolic syndr...
January 17,2026
Controlling hypertension can reduce dementia risk—even when ...
January 16,2026
Assessing methods for improving access to trauma care for ki...
January 15,2026
Portable device could help scientists track Alzheimer's dise...
January 14,2026
Neurons use physical signals, not electricity, to stabilize ...
January 13,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?Uses, Procedure, and ResultsByLynne Eldridge, MDUpdated on June 13, 2023Medically reviewed byDoru Paul,
Oncology March 17,2024
Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?Uses, Procedure, and ResultsByLynne Eldridge, MDUpdated on June 13, 2023Medically reviewed byDoru Paul,
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Dr. Fauci among hundreds who've contract...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
Announcement of the 2025 Nobel Prize in ...
More News
Synthetic peptide acts as molecular shield to prevent SARS-CoV-2 from infecting cells

Synthetic peptide acts as molecular shield to prevent SARS-CoV-2 from infecting cells

by Julia Moióli,FAPESPThe figure shows the interaction between the synthetic ACE2 peptide (yellow) and the SARS-CoV-2 spike protein. The spikes of the original viral strain from Wuhan and the om
Public Health & Prevention October 21,2024
Synthetic peptide acts as molecular shield to prevent SARS-CoV-2 from infecting cells

Synthetic peptide acts as molecular shield to prevent SARS-CoV-2 from infecting cells

by Julia Moióli,FAPESPThe figure shows the interaction between the synthetic ACE2 peptide (yellow) and the SARS-CoV-2 spike protein. The spikes of the original viral strain from Wuhan and the om
Public Health & Prevention October 21,2024
Precision breast cancer trial shows improved treatment by tumor subtype

Precision breast cancer trial shows improved treatment by tumor subtype

byUniversity of California, San FranciscoEfficacy of Dato-DXd + durvalumab treatment. Credit:Nature Medicine(2024). DOI: 10.1038/s41591-024-03267-1Despite recent advances in the trea
Oncology October 21,2024
Precision breast cancer trial shows improved treatment by tumor subtype

Precision breast cancer trial shows improved treatment by tumor subtype

byUniversity of California, San FranciscoEfficacy of Dato-DXd + durvalumab treatment. Credit:Nature Medicine(2024). DOI: 10.1038/s41591-024-03267-1Despite recent advances in the trea
Oncology October 21,2024
Clinical trial finds new drug significantly extends lives of breast cancer patients

Clinical trial finds new drug significantly extends lives of breast cancer patients

byLudwig Maximilian University of MunichKaplan–Meier analysis of key efficacy endpoints in patients with baseline BMs. Credit:Nature Medicine(2024). DOI: 10.1038/s41591-024-03261-7Pa
Oncology October 21,2024
Clinical trial finds new drug significantly extends lives of breast cancer patients

Clinical trial finds new drug significantly extends lives of breast cancer patients

byLudwig Maximilian University of MunichKaplan–Meier analysis of key efficacy endpoints in patients with baseline BMs. Credit:Nature Medicine(2024). DOI: 10.1038/s41591-024-03261-7Pa
Oncology October 21,2024
Experts release the latest guide for systematic reviews of preclinical research

Experts release the latest guide for systematic reviews of preclinical research

byRadboud UniversityCredit: Unsplash/CC0 Public DomainA new publication inNature Reviews Methods Primersprovides essential guidance for conducting rigorous systematic reviews on stud
Breakthroughs October 21,2024
Experts release the latest guide for systematic reviews of preclinical research

Experts release the latest guide for systematic reviews of preclinical research

byRadboud UniversityCredit: Unsplash/CC0 Public DomainA new publication inNature Reviews Methods Primersprovides essential guidance for conducting rigorous systematic reviews on stud
Breakthroughs October 21,2024
Reducing sitting by about 40 minutes daily may prevent back pain, research suggests

Reducing sitting by about 40 minutes daily may prevent back pain, research suggests

byUniversity of TurkuChange in back pain intensity on a scale from 0 to 10. The blue bars represent individuals in the intervention group that reduced sitting and the red bars represent the cont
Orthopedics & Sports medicine October 21,2024
Reducing sitting by about 40 minutes daily may prevent back pain, research suggests

Reducing sitting by about 40 minutes daily may prevent back pain, research suggests

byUniversity of TurkuChange in back pain intensity on a scale from 0 to 10. The blue bars represent individuals in the intervention group that reduced sitting and the red bars represent the cont
Orthopedics & Sports medicine October 21,2024
Event-free survival extended with long-term finerenone in heart failure

Event-free survival extended with long-term finerenone in heart failure

by Elana GotkineLong-term treatment with finerenone is estimated to extend event-free survival among people with heart failure with mildly reduced or preserved ejection fraction, according to a brief
Cardiovascular Diseases October 21,2024
Event-free survival extended with long-term finerenone in heart failure

Event-free survival extended with long-term finerenone in heart failure

by Elana GotkineLong-term treatment with finerenone is estimated to extend event-free survival among people with heart failure with mildly reduced or preserved ejection fraction, according to a brief
Cardiovascular Diseases October 21,2024
GLP-1 weight-loss meds could interfere with endoscopy, colonoscopy

GLP-1 weight-loss meds could interfere with endoscopy, colonoscopy

by Ernie MundellFood left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or colonoscopy.Now, research finds this scenario is more like
Diabetes & Endocrinology October 21,2024
GLP-1 weight-loss meds could interfere with endoscopy, colonoscopy

GLP-1 weight-loss meds could interfere with endoscopy, colonoscopy

by Ernie MundellFood left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or colonoscopy.Now, research finds this scenario is more like
Diabetes & Endocrinology October 21,2024
New web portal empowers drug discovery, systems-level analysis of critical kinase-substrate interactions

New web portal empowers drug discovery, systems-level analysis of critical kinase-substrate interactions

byThe Mount Sinai HospitalKiNet functionalities. Credit:npj Systems Biology and Applications(2024). DOI: 10.1038/s41540-024-00442-5Researchers from the Icahn School of Medicine at Mo
Breakthroughs October 21,2024
New web portal empowers drug discovery, systems-level analysis of critical kinase-substrate interactions

New web portal empowers drug discovery, systems-level analysis of critical kinase-substrate interactions

byThe Mount Sinai HospitalKiNet functionalities. Credit:npj Systems Biology and Applications(2024). DOI: 10.1038/s41540-024-00442-5Researchers from the Icahn School of Medicine at Mo
Breakthroughs October 21,2024
Common diabetes drug shows promise for treating macular degeneration

Common diabetes drug shows promise for treating macular degeneration

byUniversity of Chicago Medical CenterMetformin 500mg tablets. Credit: public domainAge-related macular degeneration (AMD) is one of the leading causes of vision loss in adults over 50 in the Un
Ophthalmology October 21,2024
Common diabetes drug shows promise for treating macular degeneration

Common diabetes drug shows promise for treating macular degeneration

byUniversity of Chicago Medical CenterMetformin 500mg tablets. Credit: public domainAge-related macular degeneration (AMD) is one of the leading causes of vision loss in adults over 50 in the Un
Ophthalmology October 21,2024
New book explores the history of the phony cancer drug Krebiozen

New book explores the history of the phony cancer drug Krebiozen

by Sharita Forrest,University of Illinois at Urbana-ChampaignCredit: 3 Fields BooksIn March 1951, Andrew Ivy—at the time, one of the most renowned scientists and medical ethicists in the U.S.—he
Oncology October 21,2024
New book explores the history of the phony cancer drug Krebiozen

New book explores the history of the phony cancer drug Krebiozen

by Sharita Forrest,University of Illinois at Urbana-ChampaignCredit: 3 Fields BooksIn March 1951, Andrew Ivy—at the time, one of the most renowned scientists and medical ethicists in the U.S.—he
Oncology October 21,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... Health spending has been rising across rich countries with different systems ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com